PubMed · 7415955
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
P W Willard. 1980. Regulatory indecision . . .. https://pubmed.ncbi.nlm.nih.gov/7415955/
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
Cast iron has been used as a reactive material in permeable reactive barriers (PRBs) for site remediation. While reactions are generally believed to occur on the iron (oxide) surface, a recent study by [Oh, S.Y., Cha, D.K., Chiu, P.C., 2002a. Graphite-mediated reduction of 2,4-dinitrotoluene with elemental iron. Environ. Sci. Technol. 36 (10), 2178-2184] showed that graphite inclusions in cast iron can also serve as reaction sites for 2,4-dinitrotoluene (DNT). These authors also found that graphite-mediated reduction of DNT has a regioselectivity that is different from that for iron surface. In this study, we quantified the observations reported by Oh et al. and examined the role of graphite in cast iron through numerical modelling. Models containing one and two reaction sites were developed to evaluate the mass transfer, sorption and reaction rates for DNT reduction in batch systems containing high-purity and cast iron. Our simulations showed that the regioselectivity, defined as the ratio of the ortho- and para-nitro reduction rate constants, was 0.37+/-0.04 S.E. (S.E.=one estimated standard error) for iron surface and 3.59+/-0.76 S.E. for graphite surface. In the cast iron-water system, we estimated that at least 66+/-2% S.E. of the DNT was reduced on graphite surface, despite the low graphite content and the lower DNT reduction rate with graphite than with iron. Graphite played such an important role because of the rapid adsorption of DNT to graphite. In the batch experiments conducted by Oh et al., external mass transfer was not rate limiting. Surface reaction was the rate-limiting step for DNT reduction on the graphite surface in cast iron, whereas internal mass transfer and/or adsorption and surface reaction were important for high-purity iron.
The leukocyte integrin lymphocyte function-associated antigen 1 (LFA-1) and its endothelial ligand intercellular adhesion molecule (ICAM)-1 play an important role in transmigration as demonstrated by in vivo and in vitro models of inflammation. Despite the prominent role, little is known concerning the distribution and dynamic behavior of these adhesion molecules during leukocyte transmigration. Therefore, we examined the spatial and temporal distribution of LFA-1 on neutrophils actively transmigrating tumor necrosis factor-alpha-activated human umbilical vein endothelial monolayers under shear flow. Upon neutrophil arrest, LFA-1 was evenly distributed. However, once neutrophils initiated transmigration, LFA-1 rapidly redistributed to form a ringlike cluster at the neutrophil-endothelial junctional interface through which transmigration occurred. As transmigration was completed, LFA-1 redistributed to the neutrophil uropod. Endothelial ICAM-1 and JAM-A both colocalized with the ringlike LFA-1 cluster. Further analysis of PMA-stimulated neutrophils, which increase mobility of LFA-1, showed a rapid redistribution of LFA-1 and ICAM-1, but not endothelial JAM-A. Thus, endothelial JAM-A does not appear to contribute to adhesion or transmigration in this system. This is the first demonstration that neutrophil LFA-1 rapidly redistributes to form a ringlike structure that coclusters with endothelial ICAM-1 as the neutrophil transmigrates.
The International Mesothelioma Interest Group sponsored its 7th international meeting in Brescia, Italy from June 24-26, 2004. The meeting, entitled 'How advanced technology and new drugs are changing the perspectives of patients with malignant mesothelioma', was organized by Luciano Mutti (Vercelli, Italy) and GF Tassi (Brescia, Italy) and was attended by 350 participants. The general tone of the meeting was that real progress is now coming in the understanding of mesothelioma biology, progress that may soon translate into improved treatment options. The investigators and clinicians agreed on the importance of referring patients with mesothelioma to centers with expertise where patients can receive the best available treatments and can be offered entry into clinical trials of new and promising agents.